JP2025508402A5 - - Google Patents
Info
- Publication number
- JP2025508402A5 JP2025508402A5 JP2024548368A JP2024548368A JP2025508402A5 JP 2025508402 A5 JP2025508402 A5 JP 2025508402A5 JP 2024548368 A JP2024548368 A JP 2024548368A JP 2024548368 A JP2024548368 A JP 2024548368A JP 2025508402 A5 JP2025508402 A5 JP 2025508402A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- amino
- pharmaceutically acceptable
- phase
- azaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202211009181 | 2022-02-21 | ||
| IN202211009181 | 2022-02-21 | ||
| PCT/IB2023/051532 WO2023156979A1 (en) | 2022-02-21 | 2023-02-20 | Pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508402A JP2025508402A (ja) | 2025-03-26 |
| JP2025508402A5 true JP2025508402A5 (https=) | 2026-02-20 |
Family
ID=85476156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548368A Pending JP2025508402A (ja) | 2022-02-21 | 2023-02-20 | 医薬製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250161223A1 (https=) |
| EP (1) | EP4482471A1 (https=) |
| JP (1) | JP2025508402A (https=) |
| KR (1) | KR20240150600A (https=) |
| CN (1) | CN118715005A (https=) |
| AU (1) | AU2023221615A1 (https=) |
| CA (1) | CA3251234A1 (https=) |
| IL (1) | IL314206A (https=) |
| MX (1) | MX2024009967A (https=) |
| TW (1) | TW202342040A (https=) |
| WO (1) | WO2023156979A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4580606A1 (en) * | 2022-08-31 | 2025-07-09 | Astrazeneca AB | Pharmaceutical formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| CN112867718B (zh) | 2018-09-29 | 2025-03-04 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| IL305106B2 (en) | 2018-09-29 | 2025-08-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| MX2021009562A (es) | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. |
| US20220152026A1 (en) | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| EP3923941B1 (en) | 2019-02-12 | 2025-12-03 | Novartis AG | Pharmaceutical combination comprising tno155 and ribociclib |
| EP4110338A1 (en) | 2020-02-28 | 2023-01-04 | Novartis AG | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
-
2023
- 2023-02-18 TW TW112105963A patent/TW202342040A/zh unknown
- 2023-02-20 US US18/839,600 patent/US20250161223A1/en active Pending
- 2023-02-20 KR KR1020247030717A patent/KR20240150600A/ko active Pending
- 2023-02-20 CN CN202380021982.XA patent/CN118715005A/zh active Pending
- 2023-02-20 JP JP2024548368A patent/JP2025508402A/ja active Pending
- 2023-02-20 WO PCT/IB2023/051532 patent/WO2023156979A1/en not_active Ceased
- 2023-02-20 AU AU2023221615A patent/AU2023221615A1/en active Pending
- 2023-02-20 IL IL314206A patent/IL314206A/en unknown
- 2023-02-20 CA CA3251234A patent/CA3251234A1/en active Pending
- 2023-02-20 MX MX2024009967A patent/MX2024009967A/es unknown
- 2023-02-20 EP EP23708903.2A patent/EP4482471A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2393485B1 (en) | Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir | |
| JP6122098B2 (ja) | オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物 | |
| WO2011111818A1 (ja) | モサプリドまたはその塩を含む徐放型医薬組成物 | |
| TWI700100B (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物及其製備方法 | |
| KR102766096B1 (ko) | Akt 단백질 키나아제 저해제를 포함하는 약학 조성물 | |
| JP2007091758A5 (https=) | ||
| JP6001763B2 (ja) | 低用量エンテカビルの経口投与製剤の製造方法 | |
| CA2371231A1 (en) | Pharmaceutical composition in unit form containing acetylsalicylic acid and clopidogrel hydrogenosulphate | |
| JP2024511991A (ja) | ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態 | |
| KR20230008190A (ko) | 수용성 원료의약품의 약학적 과립화제 | |
| WO2015110952A1 (en) | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof | |
| CN114642639A (zh) | 一种枸橼酸托法替布缓释组合物及其制备方法 | |
| JP2025508402A5 (https=) | ||
| CN106860414A (zh) | 一种用于抗hiv的复方制剂及其制备方法与应用 | |
| TWI436760B (zh) | 阿利克侖之蓋崙（ｇａｌｅｎｉｃａｌ）調配物 | |
| CN111888477B (zh) | 一种贝达喹啉药物制剂 | |
| TWI707682B (zh) | 醫藥劑型 | |
| RU2024127590A (ru) | Фармацевтический состав | |
| JP2022046737A (ja) | 安定性及び溶出率が改善されたタダラフィル含有及びタムスロシン含有のカプセル複合製剤 | |
| KR20180060705A (ko) | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제 | |
| CN105232551A (zh) | 一种缬沙坦/苯磺酸氨氯地平复方制剂及其制备方法 | |
| CN105636581A (zh) | 药物组合物 | |
| AU2015200637B2 (en) | Tablets for combination therapy | |
| WO2015150944A1 (en) | Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof | |
| JP2022136252A (ja) | エゼチミブ含有経口製剤及びその製造方法 |